Latest / Glaucoma, Vision & Longevity: Supplements & Science / First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma?

Transcript

First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma? · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: First human ER-100 results.
• 0:02
  SPEAKER_00: Did epigenetic reprogramming actually restore some vision in glaucoma?
• 0:06
  SPEAKER_00: Evidence cutoff, October 12th, 2026.
• 0:10
  SPEAKER_00: Bottom line, Life Biosciences has reported an intriguing first human visual field signal, but it has not shown that ER-100 restored lost vision.
• 0:19
  SPEAKER_00: The company says that two of three people with open angle glaucoma had more than a 4-decibel improvement at at least 28% of visual field test locations at day 56.
• 0:30
  SPEAKER_00: On the registered test pattern, that is about 15 locations.
• 0:34
  SPEAKER_00: That is worth investigating.
• 0:36
  SPEAKER_00: But the public report does not include the patient's visual field charts, their baseline measurements, repeat test confirmation, global visual field scores, or results from the untreated eyes.
• 0:48
  SPEAKER_00: It also does not establish that the improvement occurred in previously damaged areas or that it reflects retinal ganglion cell recovery rather than visual field variability, learning, or another measurement effect.
• 1:00
  SPEAKER_00: ER-100 may be the first reported human signal for this partial reprogramming approach.
• 1:07
  SPEAKER_00: It is not the first human suggestion that some glaucomatous visual dysfunction can improve.
• 1:13
  SPEAKER_00: Earlier studies have reported improved retinal or visual field measures after pressure reduction and other interventions, nor do the three ER-100 cases establish that this particular treatment reversed damage.
• 1:26
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 1:31
  SPEAKER_00: The main clinical facts come from Life Biosciences' October 8th announcement and the trial registry.
• 1:38
  SPEAKER_00: The company's release reports the visual field threshold.
• 1:41
  SPEAKER_00: The registry describes the trial's design and planned measurements.
• 1:45
  SPEAKER_00: What was actually disclosed?
• 1:47
  SPEAKER_00: Treatment and follow-up.
• 1:48
  SPEAKER_00: The October 8th, 2026 announcement concerned three participants with open-angle glaucoma who received one intravitreal injection of ER100 at dose level 1, 2 10 SWON vector genomes in one eye.
• 2:01
  SPEAKER_00: They took daily oral doxycycline for 56 days to induce expression of OCT4, SOX-2, and KLF-4, known together as OSK.
• 2:11
  SPEAKER_00: The company also reported an oral prednisolone taper intended to reduce inflammation related to the adeno-associated virus type 2 vector.
• 2:20
  SPEAKER_00: It did not disclose the steroid dose or taper schedule in the release.
• 2:24
  SPEAKER_00: The company said that visual field improvement was observed in two of the three participants at day 56.
• 2:31
  SPEAKER_00: In both, at least 28% of visual field locations showed an improvement of more than 4 decibels.
• 2:37
  SPEAKER_00: The Data Safety Monitoring Board recommended moving to dose level 2, 6 x 10 sensine vector genomes, 3 times the first dose.
• 2:46
  SPEAKER_00: The trial is open label, non-randomized, and primarily designed to evaluate safety and tolerability.
• 2:53
  SPEAKER_00: Its registry describes sequential dose escalation in glaucoma, followed by a separate cohort with non-arteritic anterior ischemic optic neuropathy.
• 3:02
  SPEAKER_00: The full study is planned to follow participants for as long as five years.
• 3:06
  SPEAKER_00: What I could verify about the presentation and reporting Life Biosciences announced that it would present the results at iCelerator during the American Academy of Ophthalmology meeting.
• 3:17
  SPEAKER_00: The event listing confirms the October 8th iCelerator program.
• 3:21
  SPEAKER_00: As of October 12th, the material I could verify that gives detailed human results is the company's release.
• 3:28
  SPEAKER_00: I could not locate a publicly accessible patient-level slide deck, visual field printouts, presentation transcript, or detailed independent conference account.
• 3:39
  SPEAKER_00: Available news summaries largely repeat the company's reported numbers rather than adding patient-level data.
• 3:46
  SPEAKER_00: That distinction matters.
• 3:47
  SPEAKER_00: The reported threshold is a company reported observation, not a publicly inspectable result that outside clinicians can reanalyze.
• 3:55
  SPEAKER_00: What is and is not known about the three participants then?
• 3:59
  SPEAKER_00: The trial registry supplies eligibility limits.
• 4:02
  SPEAKER_00: It does not provide the first three participants' individual clinical records.
• 4:07
  SPEAKER_00: The company has not released a patient-by-patient table.
• 4:10
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 4:15
  SPEAKER_00: For the glaucoma cohort, the registry defines eligible visual field loss as mean deviation from minus 6 to minus 20 decibels and an eligible eye pressure value below 30 mm of mercury.
• 4:27
  SPEAKER_00: These limits should not be mistaken for the actual values of the three treated participants.
• 4:33
  SPEAKER_00: What does 28% of points improved by more than 4 decibels mean?
• 4:37
  SPEAKER_00: About 15 locations, not 28% of vision restored.
• 4:42
  SPEAKER_00: The 24-2 visual field pattern tests points across the central visual field.
• 4:47
  SPEAKER_00: Depending on whether the blind spot locations are counted in the denominator, the conventional point count is 52 or 54.
• 4:54
  SPEAKER_00: 28% of either count is about 15 locations.
• 4:58
  SPEAKER_00: This does not mean that 28% of lost vision came back.
• 5:02
  SPEAKER_00: A visual field test records sensitivity at discrete locations.
• 5:06
  SPEAKER_00: The company did not report how large the average improvement was, how much each location had been damaged, or what happened at the remaining locations.
• 5:16
  SPEAKER_00: A change greater than 4 decibels at a previously impaired location could be important if it is repeatable.
• 5:23
  SPEAKER_00: But a list of points crossing a threshold is not the same as an overall improvement in the visual field.
• 5:29
  SPEAKER_00: Improvements in some locations can coexist with worsening or unchanged sensitivity elsewhere.
• 5:35
  SPEAKER_00: The registry identifies change in overall mean deviation as a visual field measure.
• 5:41
  SPEAKER_00: The announcement instead highlights the percentage of locations crossing the 4 decibel threshold.
• 5:46
  SPEAKER_00: Neither the maps nor the global scores were released.
• 5:49
  SPEAKER_00: The Crucial Unanswered Questions.
• 5:52
  SPEAKER_00: The public disclosure does not show whether the improved locations formed a coherent cluster or were scattered, whether those locations matched previously damaged areas, whether the same locations improved on a second or third post-treatment test, whether other locations worsened enough to offset the gains, changes in mean deviation, visual field index, or pattern standard deviation, whether the untreated fellow eye changed similarly.
• 6:20
  SPEAKER_00: Those details would help distinguish a plausible recovery pattern from a noisy or broadly shifted test result.
• 6:27
  SPEAKER_00: How often can a visual field point improve by more than 4 decibels by chance?
• 6:32
  SPEAKER_00: Variability is greatest in damaged regions.
• 6:34
  SPEAKER_00: A visual field result is not a perfectly stable reading of nerve function.
• 6:39
  SPEAKER_00: The pointwise test-retest variability differs by location and by the amount of existing damage.
• 6:45
  SPEAKER_00: In a study of glaucoma patients tested repeatedly, sensitivity at locations with moderate loss sometimes ranged from a near-normal result to an absolute defect across tests.
• 6:56
  SPEAKER_00: Other work finds greater variability at lower sensitivities, with a measurement floor affecting very advanced damage.
• 7:03
  SPEAKER_00: A large study of 4,044 glaucoma eyes found substantial overall test-retest variation and found that test results at central locations tended to be more correlated across tests than those at peripheral locations.
• 7:18
  SPEAKER_00: That overall measure is not a point-specific probability that a four decibel improvement will happen, but it reinforces why a one-time change needs context.
• 7:27
  SPEAKER_00: For a rough illustration, not a patient-specific estimate, if a damaged location has a paired test-to-retest different standard deviation of 3 decibels, a one-sided improvement greater than 4 decibels would occur about 9% of the time under a simple bell curve model.
• 7:43
  SPEAKER_00: If that standard deviation is 6 decibels, the estimate is about 25%.
• 7:48
  SPEAKER_00: At a relatively healthy location, variability is much lower, so a 4 decibel gain is much less likely.
• 7:56
  SPEAKER_00: Published descriptions of parametric variability support a wide range rather than one universal probability for every point.
• 8:03
  SPEAKER_00: Why 15 points cannot be treated as 15 independent coin flips?
• 8:08
  SPEAKER_00: Visual field locations are not independent.
• 8:11
  SPEAKER_00: A participant's alertness, fatigue, fixation, test comprehension, and general performance can influence many locations in the same session.
• 8:20
  SPEAKER_00: Learning can also improve results across a field.
• 8:23
  SPEAKER_00: Those shared influences make a cluster of improved points more likely than a calculation that assumes every point fluctuates independently.
• 8:32
  SPEAKER_00: To show how much the answer depends on assumptions, consider an illustrative correlated error model for 52 locations.
• 8:39
  SPEAKER_00: Suppose each location has a 10% chance of improving by more than 4 decibels from measurement variation alone.
• 8:46
  SPEAKER_00: If locations were independent, the chance of at least 15 improvements would be about 0.04%.
• 8:53
  SPEAKER_00: With modest positive correlation among locations, a rough overdispersed model puts it in the low single digits rather than near zero.
• 9:02
  SPEAKER_00: If the individual location chance were 20%, the corresponding estimate could range from roughly 8% under independence to about 15 to 30% under illustrative positive correlation assumptions.
• 9:15
  SPEAKER_00: These are sensitivity calculations, not estimates of what happened to these participants.
• 9:20
  SPEAKER_00: They assume a simplified common degree of pointwise variability and correlation.
• 9:25
  SPEAKER_00: Actual fields mix normal, moderately damaged, and severely damaged locations.
• 9:30
  SPEAKER_00: The true chance for any of the three participants cannot be calculated without their baseline and repeat fields, test reliability values, and pointwise error structure.
• 9:40
  SPEAKER_00: Still, the exercise shows why 15 points is not automatically extraordinary and why the raw maps and repeated tests are essential.
• 9:49
  SPEAKER_00: Learning, regression to the mean, and test quality.
• 9:53
  SPEAKER_00: In one study of newly tested glaucoma patients, average mean deviation improved by 2.81 decibels between the first and second test sessions, with no significant improvement between later sessions.
• 10:05
  SPEAKER_00: That result cannot simply be assigned to ER-100 participants.
• 10:09
  SPEAKER_00: Their prior perimetry experience is unknown.
• 10:12
  SPEAKER_00: But it makes the absence of a documented pretreatment testing history important.
• 10:17
  SPEAKER_00: If a baseline test happened to be unusually poor, a later test may look better even without treatment, a form of regression to the mean.
• 10:26
  SPEAKER_00: Fatigue, fixation, false positive responses, and test quality can also affect results.
• 10:32
  SPEAKER_00: The trial registry defines baseline as assessments before ER-100 administration, but the public record and company release do not tell us whether the visual field baseline was established with repeated reliable tests.
• 10:44
  SPEAKER_00: A major glaucoma study for comparison used the average of two baseline fields for assessing change.
• 10:52
  SPEAKER_00: Assessment.
• 10:53
  SPEAKER_00: A gain exceeding 4 decibels at an impaired point is not by itself proof of recovery.
• 10:59
  SPEAKER_00: A repeatable cluster in areas known to be damaged beyond that participant's own baseline variability would be much more compelling.
• 11:06
  SPEAKER_00: Was the 28% 4 decibel endpoint planned in advance?
• 11:10
  SPEAKER_00: Clinicaltrials.gov first posted the trial in December 2025 and was last updated in May 2026 before the October announcement.
• 11:19
  SPEAKER_00: The registered visual field measure is change in Humphrey visual field results, reported as mean deviation, with baseline to day 56 and baseline to day 112 time points.
• 11:31
  SPEAKER_00: The public record does not identify at least 28% of points improving by more than 4 decibels as a registered outcome.
• 11:39
  SPEAKER_00: I could not locate a public statistical analysis plan or abstract documenting that exact threshold in advance.
• 11:46
  SPEAKER_00: That does not prove the company chose the measure only after seeing the data.
• 11:50
  SPEAKER_00: It may have been in a protocol or analysis plan that is not public.
• 11:54
  SPEAKER_00: The accurate conclusion is narrower.
• 11:57
  SPEAKER_00: The exact 28% for decibel result is not verifiably pre-specified from the public record.
• 12:03
  SPEAKER_00: Until the company provides the protocol or analysis plan, it should be treated as exploratory.
• 12:09
  SPEAKER_00: Selecting a striking result after looking across multiple outcomes, time points, or locations can make chance findings look more persuasive than they are.
• 12:18
  SPEAKER_00: Did other measurements support visual field improvement?
• 12:22
  SPEAKER_00: The trial registry includes planned assessment of visual field mean deviation, best corrected visual acuity, pattern electroretinography, a measure of retinal response to visual patterns, optical coherence tomography measurements of retinal nerve fiber layer and ganglion cell layer thickness, immune response measures related to the vector.
• 12:43
  SPEAKER_00: The trial plans short-term assessments through day 56 and day 112, and longer follow-up measurements.
• 12:51
  SPEAKER_00: The October 8th release did not report numerical results for these structural or electrophysiological outcomes.
• 12:57
  SPEAKER_00: It also did not report optical coherence tomography and geography, visual-evoked potentials, contrast sensitivity, color vision, or pupillary response results.
• 13:07
  SPEAKER_00: The public record does not establish whether all of those additional tests were performed in these three participants.
• 13:15
  SPEAKER_00: The lack of reported structural or electrophysiological results does not mean those tests were negative.
• 13:21
  SPEAKER_00: It means readers cannot use them to corroborate the visual field finding.
• 13:25
  SPEAKER_00: A consistent change in visual field testing and retinal electrophysiology would be more persuasive than either alone.
• 13:33
  SPEAKER_00: Structural changes also need cautious interpretation.
• 13:37
  SPEAKER_00: An apparent increase in retinal thickness would not by itself prove that new healthy nerve fibers had formed.
• 13:43
  SPEAKER_00: What the biology does and does not make plausible, partial, is not full cellular reprogramming.
• 13:49
  SPEAKER_00: Full cellular reprogramming can erase a mature cell's identity and return it toward a pluripotent stem cell-like state.
• 13:56
  SPEAKER_00: ER100 uses three transcription factors, OC4, SOX2, and KLF4, rather than the full four-factor combination commonly associated with induced pluripotency.
• 14:08
  SPEAKER_00: Its doxycycline controlled system is intended to limit when OSK is expressed.
• 14:13
  SPEAKER_00: The proposed goal is not to turn a retinal ganglion cell into a stem cell.
• 14:18
  SPEAKER_00: It is to alter gene regulation patterns while keeping the cell's identity.
• 14:23
  SPEAKER_00: But the public human data do not demonstrate that this reprogramming occurred in the treated eyes, that it was confined to retinal ganglion cells, or that it stayed within a safe range.
• 14:33
  SPEAKER_00: Doxycycline is an intended expression control.
• 14:36
  SPEAKER_00: It does not remove the vector from the eye.
• 14:39
  SPEAKER_00: The animal evidence is real, but it is not human-proof.
• 14:42
  SPEAKER_00: A 2020 nature study reported that OSK expression in mouse retinal ganglion cells restored younger-looking DNA methylation and gene expression patterns, supported axon regeneration after injury, improved cell survival, and restored some visual function in mouse models of glaucoma and aging.
• 15:02
  SPEAKER_00: The study also reported effects in cultured human neurons, but cultured neurons are not treated patients.
• 15:09
  SPEAKER_00: Life Biosciences has also reported non-human primate results in a model designed to resemble non-arteritic anterior ischemic optic neuropathy.
• 15:18
  SPEAKER_00: Its conference disclosures described recovery of pattern electroretinogram signals and greater survival of optic nerve axons in treated animals.
• 15:27
  SPEAKER_00: These results strengthen the biological rationale, but they are company-reported preclinical results, not proof of human efficacy, and not equivalent to demonstrating that chronically damaged human glaucoma pathways regenerated.
• 15:41
  SPEAKER_00: The strongest optic-specific evidence is for epigenetic and gene expression changes, cell survival, axon growth in injury models, and electrophysiological or behavioral visual function measures.
• 15:53
  SPEAKER_00: Those studies do not establish that ER-100 restored mitochondrial function or axonal transport in the three human participants.
• 16:01
  SPEAKER_00: Those may be plausible areas of biology, but they have not been demonstrated in this human report.
• 16:07
  SPEAKER_00: Which cells could realistically explain a 56-day change?
• 16:11
  SPEAKER_00: Dead retinal ganglion cells, they cannot resume function.
• 16:15
  SPEAKER_00: ER-100 is not a cell replacement treatment.
• 16:18
  SPEAKER_00: Surviving but metabolically impaired cells, these are plausible candidates for improved function.
• 16:24
  SPEAKER_00: A living cell whose activity is suppressed may perform better without being replaced.
• 16:29
  SPEAKER_00: Living cells with impaired signal conduction, recovery is plausible if the impairment is reversible and the connection remains sufficiently intact.
• 16:38
  SPEAKER_00: Damaged but anatomically continuous axons, better function could arise if existing connections recover.
• 16:45
  SPEAKER_00: In a short time frame, this is a more plausible explanation than rebuilding an entire long-distance visual pathway.
• 16:52
  SPEAKER_00: Completely disconnected neurons.
• 16:55
  SPEAKER_00: Restoring useful vision would require axons to regrow and reconnect to appropriate brain targets.
• 17:01
  SPEAKER_00: The mouse regeneration findings make that a research possibility.
• 17:05
  SPEAKER_00: The three-participant report does not show it happened in people over 56 days.
• 17:10
  SPEAKER_00: A reasonable biological interpretation, if the visual field result is real, is improved performance by some surviving cells or axons, not replacement of neurons that had already died.
• 17:22
  SPEAKER_00: Is some glaucoma-related dysfunction reversible?
• 17:25
  SPEAKER_00: The traditional description of glaucoma emphasizes irreversible loss, and actual retinal ganglion cell death is irreversible without replacing and reconnecting the cells.
• 17:36
  SPEAKER_00: But cell death is not the same thing as all impaired function.
• 17:41
  SPEAKER_00: Human and experimental research has described retinal ganglion cells that function poorly before they are lost and has reported improvement in some functional measures after pressure reduction.
• 17:51
  SPEAKER_00: Reviews have specifically questioned whether some vision loss in glaucoma reflects a reversible period of dysfunction before cell death.
• 18:00
  SPEAKER_00: This idea has independent support, but it does not mean that every abnormal visual field point contains a recoverable living neuron.
• 18:08
  SPEAKER_00: A visual field improvement may reflect better function in surviving cells, ordinary test variation, or both.
• 18:16
  SPEAKER_00: Nor does it prove regeneration.
• 18:18
  SPEAKER_00: So ER100 is not the first human observation consistent with some reversible glaucomatous dysfunction.
• 18:25
  SPEAKER_00: Its novelty is the possibility that a partial epigenetic reprogramming treatment could be associated with a human visual field signal.
• 18:33
  SPEAKER_00: How the result compares with other ways visual field measures can improve wave pressure-lowering surgery.
• 18:39
  SPEAKER_00: Studies have reported early changes in visual field measures after trabeculectomy or other pressure reduction.
• 18:46
  SPEAKER_00: Such changes can reflect recovery of stressed but living cells, altered test performance, or both.
• 18:52
  SPEAKER_00: They do not establish that dead cells regenerated.
• 18:55
  SPEAKER_00: Cataract surgery.
• 18:57
  SPEAKER_00: In eyes with glaucoma, cataract removal has been associated with an average mean deviation improvement of about 1.68 decibels.
• 19:05
  SPEAKER_00: That is a reminder that optical clarity can shift a visual field test without repairing the optic nerve.
• 19:12
  SPEAKER_00: The ER-100 trial excludes some cataracts and recent eye surgery, but that does not replace patient-level information about the three participants' lenses and test conditions.
• 19:23
  SPEAKER_00: Nicotinamide, a randomized crossover study, reported improved retinal electrophysiology and a trend toward better visual field mean deviation.
• 19:32
  SPEAKER_00: 27% of participants improved by at least 1 decibel on nicotinamide compared with fewer deteriorating participants on placebo.
• 19:40
  SPEAKER_00: This suggests short-term functional measures can change without showing that neurons regenerated.
• 19:45
  SPEAKER_00: It does not validate high-dose self-treatment.
• 19:50
  SPEAKER_00: Learning effects.
• 19:52
  SPEAKER_00: Newly tested glaucoma patients have shown an average 2.81 decibel mean deviation improvement from the first to second test session.
• 20:00
  SPEAKER_00: Whether this applies to ER-100 participants is unknown because their prior testing experience was not disclosed.
• 20:07
  SPEAKER_00: Bramonidine.
• 20:09
  SPEAKER_00: A clinical trial has suggested less field progression in a bromonidine group than in a TMALOL group, but a Cochrane review judged the evidence too uncertain to draw firm conclusions.
• 20:19
  SPEAKER_00: That work concerns possible protection from further loss, not established restoration of lost vision.
• 20:26
  SPEAKER_00: The central comparison is not: does any other treatment produce exactly the same 28% CR4 decibel pattern?
• 20:34
  SPEAKER_00: Without ER-100's point maps and repeat tests, that comparison cannot be made.
• 20:39
  SPEAKER_00: It is that visual field sensitivity can improve for reasons other than neural regeneration, so the pattern and reproducibility matter.
• 20:47
  SPEAKER_00: Safety.
• 20:48
  SPEAKER_00: Encouraging at day 56, far from settled.
• 20:51
  SPEAKER_00: The company reported no dose limiting toxicities, serious adverse events, or adverse events of special interest attributed to ER 100 in the three participants through day 56.
• 21:03
  SPEAKER_00: It said that reported adverse events were related to the injection procedure, the steroid, or pre-existing conditions.
• 21:10
  SPEAKER_00: It did not publish the names, severity, timing, or resolution of the individual adverse events.
• 21:16
  SPEAKER_00: This is an encouraging early tolerability report, not a long-term safety demonstration.
• 21:22
  SPEAKER_00: 56 days is not enough to rule out delayed or uncommon risks involving persistent or excessive expression of reprogramming factors, loss of normal cell identity or abnormal gene expression, tumor-like growth or other consequences of cellular dysregulation, retinal toxicity, chronic or delayed inflammation, immune reactions to the vector.
• 21:43
  SPEAKER_00: These are concerns to monitor, not claims that any occurred in the three participants.
• 21:49
  SPEAKER_00: The study's planned follow up of up to five years reflects the importance of longer observation after a vector based therapy.
• 21:56
  SPEAKER_00: The company's use of a steroid taper also shows that inflammation.
• 22:00
  SPEAKER_00: Was an anticipated risk.
• 22:02
  SPEAKER_00: Escalating to 610 vector genomes may increase the number of cells reached or the level of gene expression, but a threefold increase in dose does not imply threefold efficacy.
• 22:14
  SPEAKER_00: It may also increase immune exposure and inflammatory risk.
• 22:18
  SPEAKER_00: The Data Safety Monitoring Board's recommendation supports moving to the next cohort.
• 22:23
  SPEAKER_00: It is not a finding that efficacy has been established or that delayed risks have been excluded.
• 22:29
  SPEAKER_00: How ER100 compares with other experimental approaches.
• 22:33
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 22:38
  SPEAKER_00: A Bayesian judgment, not a claim of certainty.
• 22:41
  SPEAKER_00: Three participants are too few for a stable estimate of efficacy, and the visual field result lacks public repeat test and control data.
• 22:49
  SPEAKER_00: Still, the finding is not meaningless.
• 22:51
  SPEAKER_00: It follows a biologically coherent animal program and appears in two participants rather than one.
• 22:57
  SPEAKER_00: It deserves follow-up.
• 22:59
  SPEAKER_00: Here is one transparent way to frame the uncertainty.
• 23:03
  SPEAKER_00: Before seeing these human observations, I would put the chance that a new experimental glaucoma regeneration approach would eventually show some genuine human functional effect at roughly 20%.
• 23:16
  SPEAKER_00: That is a judgment, not a published base rate.
• 23:18
  SPEAKER_00: If the reported two of three visual field signal were much more likely when ER100 truly works than when it does not, it would raise that probability.
• 23:28
  SPEAKER_00: But open label measurement, visual field variability, and an exact threshold that is not verifiably prespecified all make the same observation plausible under a no-treatment effect scenario.
• 23:40
  SPEAKER_00: A simple illustrative update, assuming the two of three result would occur in 55% of small cohorts if the treatment had a true effect, versus 25% without one, moves a 20% prior to about 35%.
• 23:54
  SPEAKER_00: Different assumptions produce different answers.
• 23:56
  SPEAKER_00: My estimates are therefore best read as explicit, revisable judgments rather than statistical outputs from the trial.
• 24:04
  SPEAKER_00: For the full table, please open this article on VisualFieldtest.com.
• 24:09
  SPEAKER_00: The chance that the three participants reported field changes reflect some actual functional improvement is higher than the chance that the study has demonstrated epigenetic rejuvenation, axon regeneration, or restored vision.
• 24:22
  SPEAKER_00: Those are different claims.
• 24:24
  SPEAKER_00: Estimates by glaucoma severity.
• 24:26
  SPEAKER_00: These are estimates that the approach could eventually show some meaningful, durable functional benefit in a well-designed study, assuming a safe and biologically active dose.
• 24:36
  SPEAKER_00: They are not probabilities that a particular patient will respond.
• 24:40
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 24:45
  SPEAKER_00: These estimates are speculative.
• 24:47
  SPEAKER_00: The first ER100 glaucoma cohort was eligible only within a moderate to advanced mean deviation range, but its individual disease severity and remaining retinal structure have not been disclosed.
• 24:59
  SPEAKER_00: Fact, strong inference, and speculation.
• 25:03
  SPEAKER_00: Fact Life Biosciences reported three participants with open-angle glaucoma treated with one low-dose intravitreal administration of ER100 and 56 days of doxycycline.
• 25:14
  SPEAKER_00: The company reported visual field improvement meeting its stated threshold in two participants and no dose limiting toxicity, serious adverse event, or special interest adverse event attributed to ER100 through day 56.
• 25:28
  SPEAKER_00: The public disclosure does not provide patient-level visual field charts or numerical structural and electrophysiological outcomes.
• 25:36
  SPEAKER_00: Strong inference.
• 25:38
  SPEAKER_00: If the changes are real and sustained, they are more likely to reflect improved function in surviving cells or axons than recovery of neurons that had already died.
• 25:48
  SPEAKER_00: Repeatable gains at the same previously damaged locations, accompanied by supporting functional measurements, would be much stronger evidence than a single set of threshold crossing points.
• 26:00
  SPEAKER_00: Current public evidence cannot separate treatment-related recovery from variation, learning, and other measurement effects.
• 26:08
  SPEAKER_00: Speculation ER100 is rejuvenating human retinal ganglion cells.
• 26:13
  SPEAKER_00: The improved locations represent genuine reversal of glaucomatous neural damage.
• 26:18
  SPEAKER_00: The higher dose will work better, the therapy will succeed in a controlled trial, or it will be approved.
• 26:24
  SPEAKER_00: The early glaucoma group will benefit more than the moderate group, or the advanced group will benefit less.
• 26:30
  SPEAKER_00: These are biologically informed predictions, not findings from the three participants.
• 26:36
  SPEAKER_00: What would make confidence rise dramatically in the next 10 to 30 participants?
• 26:41
  SPEAKER_00: The next report would be much more persuasive if it provides for each participant and each eye at least two reliable pretreatment visual fields, rather than an unexplained single baseline, all post-treatment fields at day 56, day 112, and a later follow-up.
• 26:57
  SPEAKER_00: Full point-by-point maps and global results, mean deviation, visual field index, and pattern standard deviation, with reliability measures and test conditions.
• 27:08
  SPEAKER_00: Evidence that gains recur at the same previously damaged locations on more than one post-treatment test rather than appearing once at different points.
• 27:18
  SPEAKER_00: Results for the treated and untreated eyes, with treatment changes, eye pressure, cataract status, and other testing conditions documented.
• 27:27
  SPEAKER_00: A measure chosen and published before the results are analyzed with masked visual field grading and a control group or another credible way to estimate test-retest change.
• 27:37
  SPEAKER_00: Corroboration from pattern electro-retinography or another suitable functional measure, alongside carefully interpreted retinal nerve fiber layer and ganglion cell imaging.
• 27:48
  SPEAKER_00: A meaningful difference between treated and control eyes.
• 27:52
  SPEAKER_00: For example, among 20 treated participants, at least 10 to 12 with sustained gains at the same damaged locations compared with no more than two to three comparable control participants.
• 28:04
  SPEAKER_00: Those numbers are illustrative, not a validated clinical cutoff.
• 28:08
  SPEAKER_00: Persistence after doxycycline is stopped with no concerning retinal, inflammatory, or systemic safety signal as follow-up lengthens.
• 28:16
  SPEAKER_00: A sustained improvement in overall mean deviation, say around 1.5 decibels or more, would add weight if it were greater than the control group change and accompanied by repeatable pointwise and electrophysiological findings.
• 28:30
  SPEAKER_00: That number is a useful example for judging a signal, not an established minimum clinically important difference for this trial.
• 28:38
  SPEAKER_00: Did ER100 actually reverse glaucoma damage?
• 28:42
  SPEAKER_00: Possibly, but the evidence so far does not establish that it did.
• 28:46
  SPEAKER_00: The October 8th report is a meaningful early observation.
• 28:49
  SPEAKER_00: Two of three participants reportedly crossed a pointwise visual field threshold after treatment against a plausible preclinical rationale.
• 28:58
  SPEAKER_00: It is enough to raise the probability that ER-100 could have a biological effect in people.
• 29:03
  SPEAKER_00: It is not enough to conclude that the participants recovered lost vision, that retinal ganglion cells were rejuvenated, or that optic nerve damage was reversed.
• 29:13
  SPEAKER_00: My present judgment is, possibly, a weak but biologically plausible human signal awaiting basic confirmation.
• 29:21
  SPEAKER_00: If the same damaged visual field locations improve repeatedly, the untreated eyes do not show similar changes, global field measures move in the same direction, and electrophysiology supports the finding in the next 10 to 30 people, confidence in genuine functional recovery would rise substantially.
• 29:40
  SPEAKER_00: Selected sources, Life Biosciences, October 8, 2026, ER100 announcement, Clinicaltrials.gov, ER100 Study, NCT0729244.
• 29:52
  SPEAKER_00: Iscilarator at the American Academy of Ophthalmology 2026.
• 30:04
  SPEAKER_00: Non-human primate results presented at Arvo.
• 30:07
  SPEAKER_00: Test retest variability in glaucomatous visual fields, pointwise variability in 24-2 and 10-2 visual fields, parametric learning in patients with glaucoma, cataract extraction and automated perimetry in glaucoma, nicotinamide crossover trial in glaucoma, Phase 1 study of the NT501 ciliary neurotrophic factor implant, functional recovery and retinal ganglion cell dysfunction in glaucoma, cell based therapies for glaucoma.
• 30:36
  SPEAKER_00: All links to sources are available in the text version of this article.
• 30:40
  SPEAKER_00: You can find the full article at VisualFieldtest.com.
• 30:44
  SPEAKER_00: Thanks for listening.
• 30:45
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.